High Dosage of Wegovy: Impacts on Weight Loss and Side Effects

Testing reveals that a higher weekly dosage of Wegovy is linked to an increased risk of side effects.

Prior research indicates that individuals receiving the standard weekly doses of Wegovy, which contains the active ingredient semaglutide, can lose up to 15% of their body weight over a year when combined with a healthy diet and exercise regimen. This medication mimics the action of GLP-1, a hormone akin to glucagon, which aids in numerous ways such as delaying stomach emptying and signaling the brain to suppress appetite.

Produced by the pharmaceutical company Novo Nordisk, Wegovy is approved for use among individuals with obesity or those who are overweight and possess at least one weight-related condition like type 2 diabetes. “However, some patients may not experience the desired level of weight loss or may seek more than the average 10-15% reduction,” says Lora Heisler, who was not part of the research team from the University of Aberdeen in the UK.

To explore the potential benefits of increased dosage, Shawn Wharton and colleagues, including scientists from the University of Toronto and Novo Nordisk, studied over 1,000 obese adults across 11 countries, including the United States, Canada, and parts of Europe.

Participants, all without diabetes, were randomly assigned to receive either a high dosage of 7.2 milligrams or the standard 2.4 milligrams of semaglutide, alongside a placebo injection mimicking Wegovy. Doses of semaglutide were gradually elevated over several weeks, and all participants were encouraged to maintain a caloric deficit of 500 calories per day and engage in physical activity for 150 minutes weekly.

After one year, those receiving the standard dosage lost an average of 16% of their body weight, while the high-dose group achieved about 19% weight loss. Conversely, the placebo group lost approximately 44% of their body weight.

One-third of participants in the standard dosage category experienced over 20% weight loss, compared to almost half in the high-dose group. Only 3% in the placebo group reached this threshold, indicating that higher dosages can significantly enhance weight loss outcomes, according to Heisler.

At the onset of the study, more than one-third of participants in each group had prediabetes, marked by elevated blood sugar levels without qualifying for type 2 diabetes. By the study’s conclusion, diabetes cases in the high-dose group decreased by 83%, while cases within the standard-dose group fell by 74%. “This is highly encouraging, as the main objective of weight loss is to enhance overall health,” Heisler remarks.

Nevertheless, there are noteworthy drawbacks. Bowel-related side effects, such as nausea, vomiting, and diarrhea, were reported by 61% in the standard-dose group, while 71% in the high-dose category experienced similar issues. In comparison, 40% of those taking the placebo also faced these symptoms, which might not be directly related to the treatment, according to Heisler.

Moreover, over 20% of the high-dose group reported unpleasant skin sensations known as dysesthesia. As a result, four participants discontinued their treatment. By contrast, only 6% of the standard-dose recipients and just one in the placebo group reported this side effect, with no one ceasing treatment.

These findings indicate that the advantages of higher dosages may outweigh the associated risks for certain individuals, according to Heisler. “For those requiring substantial weight loss who don’t experience many side effects, the higher dose may facilitate their goals,” she states. However, it may not be appropriate for individuals achieving sufficient weight loss on standard doses or those enduring severe side effects. She emphasizes the need for additional trials to validate these results before clinical application.

In a separate trial, Wharton and his team suggest that higher dosages might yield greater weight loss and enhanced blood glucose levels in individuals with both obesity and type 2 diabetes. However, the results were not statistically significant, indicating a need for further investigation, says Simon Cork from Anglia Ruskin University in the UK.